Chinook Therapeutics. has filed a patent for methods to improve kidney function in individuals. The claim details have been canceled. GlobalData’s report on Chinook Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Chinook Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Chinook Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Chinook Therapeutics's grant share as of January 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Improving kidney function in a subject

Source: United States Patent and Trademark Office (USPTO). Credit: Chinook Therapeutics Inc

A recently filed patent (Publication Number: US20230364055A1) outlines a method for treating IgA nephropathy in diagnosed subjects. The method involves administering a specific dosage of atrasentan, or its equivalent salt, ranging from 0.20 mg to 1.5 mg. The diagnosis of IgA nephropathy can be confirmed through a kidney biopsy, which may include detecting IgA-immune complexes or galactose-deficient IgA. Additionally, the presence of anti-glycan autoantibodies can also indicate the condition. The dosage of atrasentan administered can vary between 0.40 mg to 0.85 mg, with a specific dosage of 0.75 mg recommended in certain cases. The method excludes subjects previously diagnosed with specific conditions like diabetic nephropathy, HIV/AIDS, or acute kidney failure.

Furthermore, the patent also describes a method for reducing proteinuria in subjects with biopsy-diagnosed IgA nephropathy. This method involves administering an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), atrasentan, and optionally a diuretic. Specific ACE inhibitors like lisinopril and ARBs like losartan or olmesartan are mentioned. The diuretic component can include various options like hydrochlorothiazide or furosemide. The dosage of atrasentan administered in this method ranges from 0.40 mg to 0.85 mg, with a recommended dosage of 0.75 mg in certain cases. Similar to the previous method, subjects with a history of diabetic nephropathy, HIV/AIDS, or acute kidney failure are excluded from this treatment approach. Additionally, a method specifically targeting subjects with a brain natriuretic peptide (BNP) level of at least 200 pg/mL is outlined, with similar dosage and exclusion criteria as the previous methods.

To know more about GlobalData’s detailed insights on Chinook Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies